Novartis Clinical Trial Pipeline — 338 Active Studies

Novartis pipeline at a glance (March 2026)

About the Novartis clinical program

Novartis has a diversified late-stage pipeline spanning oncology, ophthalmology, cardiovascular, and immunology. Their radioligand therapy (RLT) franchise — anchored by Lutathera and Pluvicto (lutetium PSMA-617) — has established Novartis as the leader in targeted radiotherapy for solid tumors. In breast cancer, Kisqali (ribociclib) continues expanding into new settings against CDK4/6 inhibitor competitors. Kymriah pioneered the CAR-T category, and Novartis continues investing in next-generation cell therapies. Their ophthalmology pipeline (Luxturna gene therapy, complement inhibitors for geographic atrophy) represents a major growth vector.

Key therapeutic areas

• Oncology (radioligand, CDK4/6, CAR-T)
• Ophthalmology / gene therapy
• Cardiovascular
• Immunology / inflammation
• Neuroscience

Key pipeline programs

• Kisqali (ribociclib) — HR+ breast cancer CDK4/6 inhibitor
• Pluvicto (lutetium-177 PSMA) — metastatic prostate cancer
• Kymriah (tisagenlecleucel) — CAR-T lymphoma/leukemia
• Cosentyx (secukinumab) — IL-17A, psoriasis/ankylosing spondylitis
• Iptacopan — complement Factor B, IgA nephropathy
• Scemblix (asciminib) — BCR-ABL1 CML

Top Novartis trial indications

Condition / Indication	Trials
["Relapsing Multiple Sclerosis"]	10
["Breast Cancer"]	9
["Hidradenitis Suppurativa"]	9
["Chronic Spontaneous Urticaria"]	7
["Prostate Cancer"]	6
["Asthma"]	6
["Multiple Sclerosis"]	5
["Atherosclerotic Cardiovascular Disease"]	4

Why monitor Novartis's clinical trial activity

Novartis regularly initiates combination trials for Kisqali and Pluvicto in new patient populations. Their radioligand therapy pipeline expansion — beyond PSMA into SSTR2 and other targets — is one of the most watched programs in oncology BD.

DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Novartis's registered studies — new trial registrations, status transitions (e.g., "Not yet recruiting" → "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and real-time pipeline developments.

How DataLookout tracks Novartis trials

• Sponsor normalization: Novartis may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
• Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
• Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced — not just new registrations.
• Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
• Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.

Frequently asked questions

What is Novartis's focus in oncology clinical trials?

Novartis's oncology pipeline spans three major platforms: targeted therapies (Kisqali/ribociclib in breast cancer, Scemblix/asciminib in CML), radioligand therapies (Pluvicto in prostate, next-generation RLTs), and cell therapies (Kymriah CAR-T and successors). Their RLT platform is the most active area for new trial registrations.

How many Novartis trials are currently recruiting?

Based on current ClinicalTrials.gov data, 116 Novartis-sponsored trials are actively recruiting patients across all therapeutic areas and phases.

Can I get alerts when Novartis starts a new Phase 3 trial?

Yes. DataLookout monitors ClinicalTrials.gov daily and delivers filtered alerts when new trials matching your criteria are registered. You can filter specifically for Novartis-sponsored Phase 3 trials in any indication.